Additional Resources From myAgios Patient Support Services

The resources below can provide further support for physicians and patients regarding myAgios, pyruvate kinase (PK) deficiency, treatments, and financial support.

Resources for Physicians and Patients

myAgios Healthcare Provider Brochure

This brochure outlines all the education and support services provided by myAgios.

myAgios Patient Brochure

Helpful information for patients about PK deficiency, PYRUKYND, and myAgios support.


Resources for Patients Only

About PYRUKYND Brochure

An overview of PYRUKYND treatment for PK deficiency, as well as tools to help patients work closely with their doctor to proactively manage their condition.

Monitoring Guide

This guide can help patients keep track of the recommended tests and follow-up assessments needed for people with PK deficiency, so health trends can be identified early on.


Pyruvate Kinase Deficiency Communities on Social Media

Connect Patients to the PK Deficiency Community

The communities below can offer more support for patients living with rare diseases.

Like our pyruvate kinase deficiency community Facebook page and connect with people who have PK deficiency and their family and friends who support them.

Watch, learn, and share videos from our YouTube channel and see how we are generating awareness to support people living with PK deficiency and their families.

Call myAgios at 1-800-951-3889, Mon-Fri, 8 am to 6 pm ET.


PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.


Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see full Prescribing Information for PYRUKYND.

This program is not intended as medical advice and patients should consult their healthcare team with questions related to their treatment.